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Objective: Aberrant expression of miRNA (miR)-96 is associated with tumorigenesis and tumor progression in
several solid cancers. However, little is known about the expression and prognostic value of miR-96 in acute
myeloid leukemia (AML). Therefore, the aim of this study was to investigate the correlation of miR-96 expression
with clinicopathological features and prognosis of AML.
Methods: Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-96 in
mononuclear cells from bone marrow or peripheral blood specimens in 86 patients with newly diagnosed AML.
Results: Compared with normal controls, miR-96 expression was significantly downregulated in patients with newly
diagnosed AML (P < 0.001). In analysis of 14 diagnosis/CR-paired samples, the expression level of miR-96 was found
markedly elevated in patients after treatment than before (P < 0.001). Moreover, lower levels of miR-96 were
associated with a higher white blood cell count, bone marrow blast count (P < 0.001 and 0.022, respectively), and
lower hemoglobin and platelet count (P = 0.036 and 0.033, respectively). Although the low-expression group
seemed to have a lower CR rate (53.85% vs 70.0%), there was no significant difference between the two groups
(P = 0.213). The low-expression group had a lower relapse-free survival (RFS) (P = 0.038) and overall survival (OS)
(P = 0.022) compared with the high-expression group during a median follow-up of 20 months.
Conclusion: Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML
patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might
become a potential biomarker of prognosis and monitoring in AML.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1434808553949498
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Acute myeloid leukemia (AML) is a heterogeneous malig-
nancy characterized by differentiation arrest and malignant
proliferation of clonal myeloid precursors. Despite the
fact that the majority of AML patients achieve complete
remission (CR) after chemotherapy, only ~20% of patients
achieve relatively long-term disease-free survival. Most
of them die of either refractory or relapsed AML [1].
Karyotypes, many known valuable fusion genes in AML,
and aberrant expression of several molecules, such as* Correspondence: quanyilu@hotmail.com; cyx1228@21cn.com
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reproduction in any medium, provided the ormutations in FLT3, C-Kit, NPM1, WT1, and CEBPA genes,
are involved in diagnoses and prognosis of patients with
AML. However, it is difficult to evaluate the survival and
prognosis for most AML patients who lack characteristic
cytogenetic or molecular changes. Thus, there is a need to
find more valuable biomarkers to improve our understand-
ing of the biology of leukemia. Recently, it was reported
that variable miRNA expression signatures are also involved
in the heterogeneity of AML [2-4].
miRNAs are a class of small noncoding single-strand
RNA molecules that negatively regulate gene expression at
the post-transcriptional level by binding to 3′-untranslated
regions of their target mRNAs [5]. Increasing evidence
supports a pivotal role for miRNAs in the multiple pro-
cesses of carcinogenesis, including cell growth, apoptosis,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Recently, several studies indicated that expression of
miRNAs is associated with patient survival, and they
can function as prognostic and predictive indicators
[11-14]. Moreover, it has been found that miRNA ex-
pression profiles are more accurate to classify tumors
than mRNA profiles are [15], indicating that miRNAs
could be used as molecular biomarkers for diagnosis of
cancer and prediction of prognosis.
Several recent studies have demonstrated that the ab-
errant expression of miRNA (miR)-96 is associated with
tumorigenesis and tumor progression in several types of
cancer, including prostate cancer, urothelial carcinoma,
bladder carcinoma, hepatoma, and breast cancer [16-20].
Little is known about the expression of miR-96 in AML,
except for one study which used a microarray platform
to scan for an miRNA signature [2]. However, no clinical
correlation with miR-96 was further investigated. Thus,
the aim of the present study was to investigate the cor-
relation of miR-96 expression with clinicopathological
features and prognosis of AML.
Materials and methods
Patients and tissue samples
From July 2010 to August 2012, 86 patients were diagnosed
with de novo AML (non-M3) according to the French–
American–British (FAB) criteria at Zhongshan Hospital of
Xiamen University, China. The study was approved by the
local ethics committee of Zhongshan Hospital of Xiamen
University and informed consent was obtained from each
patient or a family member. There were 42 male and 44
female patients, with a medium age of 46 (range 11–75)
years. The median leukocyte count at diagnosis was
54,429/μL (range 710–315,000/μL). According to the
FAB classification, three patients had AML M1, 32 had
M2, 13 had M4, 34 had M5, three had M6, and one had
M7. Sixty-five patients were subjected to cytogenetic classi-
fication according to karyotyping and detection of 16 types
of common fusion genes, including AML1/ETO, PML/
RARa, CBFβ/MYH11, MLL/AF10 and DEK/CAN and four
types of mutations, namely, FLT3/ITD, NPM1, CEBPA and
C-KIT. Clinical characteristics of the patients with AML
are summarized in Table 1. Seventy-two patients received
chemotherapy and were treated with standard cytarabine
plus daunorubicin 7 + 3 induction chemotherapy. CR was
defined by the criteria proposed by Cheson et al. [21]. Pa-
tients who achieved CR were then given high- or medium-
dose cytarabine-based chemotherapy for consolidation
according to their physical condition. Those who did not
achieve CR were treated with medium-dose cytarabine-
based chemotherapy. Forty-two patients with CR were
followed up for a median 20 months (range 12–39 months).
None of patients in CR had undergone stem cell transplant-
ation until the end of follow-up because of the absence ofsuitable donors, poor condition, or other reasons. The
data were censored when the patients relapsed or died.
Bone marrow (BM) or peripheral blood (PB) specimens
(peripheral white blood cells >50 × 109) were obtained
from patients at the time of their diagnosis, and from
14 patients in CR after two cycles of chemotherapy,
after receiving informed consent. Five PB specimens
from healthy donors for allogeneic hematopoietic stem
cell transplantation were obtained as healthy controls,
with informed consent.
RNA extraction
Mononuclear cells from blood or BM specimens were iso-
lated by Ficoll gradient (lymphoprep d = 1.077; Axis-Shield,
Oslo, Norway) centrifugation for 20 min at 560 g at room
temperature, and then washed and pelleted. Additionally,
PB CD34+ cells from five healthy donors were enriched
with immunomagnetic methods (Miltenyi Biotec, Bergisch-
Gladbach, Germany; purity >90%). Total RNA was isolated
using RNAprep Pure Blood Kit (Tiangen Biotech, Beijing,
China), according to the manufacturer’s instructions,
followed by treatment with RNase-free DNase I to remove
contaminating genomic DNA. Finally, RNA was dissolved
in RNase-free water. The RNA concentration was quanti-
fied by NanoDrop ND-1000 (Nanodrop, Wilmington, DE,
USA) and stored at −80°C until use.
RT-PCR
miR-96 and U6 snRNA-specific cDNA was formed using
the Gene Amp System 9700 (Applied Biosystems, Foster
City, CA, USA). U6 snRNA was used as an internal control.
Reverse transcriptase primers for miR-96 and U6 were 5′-
GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTG
CACTGGATACGACAGCAAAA-3′ and 5′-CGCTTCAC
GAATTTGCGTGTCAT-3′. Reverse transcription condi-
tions contained 800 ng total RNA, 0.3 μl stem-loop RT pri-
mer (1 μM), 2 μl 10× RT buffer, 2 μl dNTP (2.5 mM each),
0.2 μl Moloney murine leukemia virus reverse transcript-
ase (Sangon, Beijing, China), and 0.3 μl RNase inhibitor
(40 U/μl). The 20-μl reaction volumes were incubated at
16°C for 30 min, 42°C for 40 min, 85°C for 5 min, and
then held at 4°C or stored at −20°C.
Quantitative real-time PCR
The 10-μl PCR mixture included 2 μl cDNA, 5 μl 2× Master
Mix (SuperArray Bioscience, Frederick, MD, USA), 0.5 μl
primer-F (10 μM), 0.5 μl primer-R (10 μM), and 2 μl
nuclease-free water. Forward and reverse primers for
U6 (89 bp) were 5′-GCTTCGGCAGCACATATACTA
AAAT-3′ and 5′-CGCTTCACGAATTTG-CGTGTCAT-3′.
Primers for hsa-hsa-miR-96 (66 bp) were GSP: 5′-GGT
TTGGCACTAGCACAT-3′; R: 5′-CAGTGCGTGTCGTG
GAGT-3′. Real-time PCR was performed on an ABI
PRISM7900 system (Applied Biosystems) with the following
Table 1 Clinical characteristics of 86 patients with newly diagnosed AML and expression of miR-96
Characteristics Cases miRc96 expression level x2 p
Low expression High expression
Sex Male 42 28 14 0.374 0.541
Female 44 32 12
Age <60 64 46 18 0.527 0.468
≥60 22 14 8
WBC <10 26 11 15 13.323 0.000*
≥10 60 49 11
HGB <80 54 42 12 4.415 0.036*
≥80 32 18 14
PLT <50 48 38 10 4.550 0.033*
≥50 38 22 16
Blast in BM <50% 37 21 16 5.212 0.022*
≥50% 49 39 10
FAB subtype M1/M2 35 25 10 0.791 0.673
M4/M5 47 33 14
Other 4 2 2
Cytogenitics Favorable 12 7 5 0.516 0.776
Intermediate 39 26 13
Unfavorable 14 10 4
Complete Remission Y 42 28 14 1.551 0.213
N 30 24 6
*P<0.05.
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cles of 95°C for 10 s and 60°C for 1 min. The cycle
threshold was automatically given by SDS 2.4 software
(Applied Biosystems) and was defined as the fractional
cycle number at which the fluorescence passed the
fixed threshold of 0.15. The relative expression levels
of miRNAs were calculated using the comparative ΔΔCt
method as described previously [22]. The fold changes in
miRNAs were calculated using the 2(-Delta Delta C(T))
method [23]. All experiments were performed at least
in triplicate.
Statistical analysis
SPSS version 13.0 (IBM, Armonk, NY, USA) were used
for statistical analysis. The Kruskal–Wallis nonparametric
test was used to evaluate the significant difference of
expression of miR-96 between the AML patients and
NC. The t test was used to evaluate the difference of
expression of miR-96 before and after chemotherapy.
With regard to the correlation of leukemia clinical fea-
tures with the expression level of miRNA-96, inter-
group comparisons were performed using the χ2 test.
Kaplan–Meier survival curves were used to determine
any significant relationship between the expression
level of miRNA-96 and the status of the patients withrespect to relapse-free survival (RFS) and overall sur-
vival (OS). RFS was defined as the time between the
achievement of complete remission and the time of the
hematological relapse or the last follow-up. OS was de-
fined as the time between the moment of diagnosis and
death or the last follow-up. Differences were considered
statistically significant when P was <0.05.
Results
Expression of miR-96 in AML patients
miR-96 expression was detected in BM/PB samples from
patients with AML and normal controls. Expression of
miRNA-96 was normalized with U6, and the values
obtained were compared. Consequently, the relative
abundances of miR-96 were significantly downregulated
in AML patients (mean expression value 19.26, n = 86)
compared with those of healthy controls (mean expression
value 195.43, n = 5), which was a significant difference
(Figure 1, P < 0.001). AML patients expressing miR-96 at
levels less than the median (19.26) were assigned to the
low-expression group (mean expression value 4.34, n = 60),
and those samples with expression equal to or above the
median value were assigned to the high-expression group
(mean expression value 52.06, n = 26). Moreover, 14 AML
patients who achieved CR after one or two cycles of
Figure 1 Real-time PCR quantification of miR-96 expression in
newly diagnosed AML patients and healthy controls. miR-96
expression was significantly downregulated in AML patients when
diagnosed (mean value 19.26) compared with those of healthy
controls (mean value 195.43) (P < 0.001). U6 served as an internal
normalized reference for miR-96. All experiments were performed at
least in triplicate.
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course of treatment. The mean expression value of
these AML patients when diagnosed was 23.70 and
markedly increased to 213.64 when CR was achieved
after chemotherapy (Figure 2, P < 0.001).
Correlation of miR-96 expression with clinical characteristics
of AML
The correlation of miR-96 expression with clinical char-
acteristics at time of diagnosis is summarized in Table 1.
Lower levels of miR-96 were associated with a higher
white blood cell count, BM blast count (P < 0.001 and
0.022, respectively), and lower hemoglobin and plateletFigure 2 Comparison of miR-96 expression before and after CR
in 14 AML patients. miR-96 level significantly increased after
treatment (mean value 213.64) compared with before treatment
(mean value 23.70, P < 0.001).count (P = 0.036 and 0.033, respectively). Moreover, we
failed to correlate the expression levels of miR-96 with
other clinical parameters including sex (P = 0.541), age
(P = 0.468), FAB subtype (P = 0.673) and cytogenetic
abnormalities (P = 0.776).
Association of miR-96 expression with clinical outcomes
of AML
Seventy-two newly diagnosed patients received chemother-
apy. The CR rate after two cycles of chemotherapy was
53.85% (28/52) in the low-expression group, compared with
70.0% (14/20) in the high-expression group. Although it
seemed that the low-expression group had a lower CR rate,
there was no significant difference between the two groups.
Forty-two CR patients were followed up for a median
duration of 20 months (range 12–39 months). The low-
expression group had a shorter RFS (P = 0.038) and OS
(P = 0.022). The Kaplan–Meier curves for PFS and OS
stratified according to miR-96 expression in BM from
AML patients in CR are shown in Figure 3.
Discussion
Although more recurrent chromosomes, and even chro-
matin texture features [24], are relevant to AML, it is still
not adequate for diagnosis and prognosis classification in
most AML patients. Nowadays, considerable progress has
been made in identifying, characterizing, and applying
new molecular markers [25-27], including miRNAs. It is
estimated that miRNAs may regulate up to one-third of
the human genome. Thus they represent novel biological
entities with potential value as tumor biomarkers, which
can improve diagnosis, prognosis, and monitoring of treat-
ment response for human cancers [14,28].
miR-96, together with miR-182 and miR-183, belongs to
the miR-183-96-182 cluster, which has been demonstrated
to play important roles in tumorigenesis and tumor pro-
gression [29-31]. Among these numbers, miR-96 may act
as either an oncogenic miR-96 or play an antioncogenic
role in many human malignancies. Several recent studies
have demonstrated that aberrant expression of miR-96
is associated with tumorigenesis, tumor progression, and
chemotherapy response in several types of cancer, includ-
ing urothelial carcinoma, bladder carcinoma, hepatoma,
glioma and breast cancer [17-20,30,32]. Overexpression of
miR-96 has been observed in various types of cancer. In
HepG2 hepatoma [19] and breast cancer [20] cells, overex-
pression of miR-96 induces cell proliferation and growth.
Upregulation of miR-96 in breast cancer cells modulates
their entry into the G1/S transitional phase, which is caused
by downregulation of cyclin-dependent kinase (CDK)
inhibitors, p27(Kip1) and p21(Cip1), and upregulation of
the cell-cycle regulator cyclin D1 [20]. Moreover, miR-96
promotes the migration and invasion of hepatocellular
carcinoma (HCCLM6) cells in vitro [32]. By contrast,
Figure 3 Kaplan–Meier curves for RFS and OS stratified according to miR-96 expression in BM/PB samples from 42 AML patients in CR.
RFS(Figure 3A) and OS(Figure 3B) in patients with low miR-96 expression was significantly lower than that in those with high miR-96 expression
(P < 0.05). The P-value was calculated using the log-rank test.
Zhao et al. Diagnostic Pathology 2014, 9:76 Page 5 of 6
http://www.diagnosticpathology.org/content/9/1/76accumulating studies have demonstrated that tumor-
suppressive roles of miR-96 are found in other types of
cancer. miR-96 levels are markedly decreased in pan-
creatic cancer [33]. In vitro and in vivo assays have
established that miR-96 decreases cancer cell invasion
and migration and slows tumor growth in a manner
associated with KRAS gene downregulation. In ALK-
expressing cancer cell lines and primary human tumors,
transfection with miR-96 decreases levels of the different
forms of ALK protein, and decreases the phosphorylation
of ALK target proteins, resulting in reduced proliferation,
colony formation, and migration [34]. However, the status
of miR-96 expression and its prognostic roles are unclear
in AML.
In this study, we detected the expression of miR-96 in
BM from 86 patients with newly diagnosed AML, and
showed that the relative expression level of miR-96 in
AML was significantly lower than that in normal con-
trols, which is consistent with the study of Garzon [2].
In that study, miR-96 was identified as one of 26 down-
regulated miRNAs in newly diagnosed AML, compared
with mononuclear cells obtained from healthy donors.
Then, we found that the level of miR-96 differed among
the 14 diagnosis/CR-paired samples. The expression of
miR-96 significantly increased after chemotherapy when
patients achieved CR, suggesting that expression of miR-96
is consistent with tumor burden, and expression of miR-96
can be used as a prognostic marker of relapse. We analyzed
the clinicopathological features of miR-96 in AML. Our re-
sults indicated that downregulation of miR-96 in AML was
associated with a higher white blood cell count and bone
marrow blast count, and lower hemoglobin and platelet
count, which represented more aggressive clinical featuresand also related to a larger tumor burden. Finally, we
analyzed the correlation of miR-96 expression with
prognosis of AML patients, and found that patients
with low miR-96 expression showed worse RFS and OS
than those with high miR-96 expression, which implies
that expression of miR-96 has an important value in AML
prognosis classification.
Conclusion
The results of our study indicate that expression of miR-96
was downregulated in patients with newly diagnosed AML
and associated with leukemic burden, as well as RFS and
OS. To the best of our knowledge, this is the first study to
demonstrate that miR-96 was strongly correlated with the
aggressive clinical features and poorer prognosis of AML,
suggesting that miR-96 is a potential marker for risk stratifi-
cation in the treatment of AML. However, there are many
problems to be further investigated. For example, what
is the mechanism by which miR-96 is downregulated in
AML? Are there any correlations between the expression of
miR-96 and some known prognosis factors, such as FLT3/
ITD and NPM1 mutation? What is the prognostic value
of miR-96 in the normal karyotype AML population when
the population is further enlarged? This study is hypoth-
esis generating, and further prospective analysis should be
worth doing.
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